4.34
+0(+0.00%)
Currency In USD
| Previous Close | 4.34 |
| Open | 4.33 |
| Day High | 4.34 |
| Day Low | 4.33 |
| 52-Week High | 4.58 |
| 52-Week Low | 1.37 |
| Volume | 390,873 |
| Average Volume | 97,549 |
| Market Cap | 37.54M |
| PE | -1.01 |
| EPS | -4.28 |
| Moving Average 50 Days | 4.23 |
| Moving Average 200 Days | 3.1 |
| Change | 0 |
If you invested $1000 in Lumos Pharma, Inc. (LUMO) 10 years ago, it would be worth $108.5 as of December 26, 2024 at a share price of $4.34. Whereas If you bought $1000 worth of Lumos Pharma, Inc. (LUMO) shares 5 years ago, it would be worth $1,386.58 as of December 26, 2024 at a share price of $4.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma
GlobeNewswire Inc.
Dec 12, 2024 1:47 PM GMT
AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Venture
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
GlobeNewswire Inc.
Nov 21, 2024 2:00 PM GMT
AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
GlobeNewswire Inc.
Oct 30, 2024 8:05 PM GMT
AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210
Data not available